Biotechnology & Biotechnological Equipment · 2022 · 10 citations · 46 references
MedicineImmunologyOncologyCancer ImmunologyTumor ImmunologyTumor MicroenvironmentColorectal CancerGastrointestinal ImmunologyGastrointestinal InflammationImmune Cell InfiltrationRegulatory T CellsTumor Immune MicroenvironmentColonic InflammationColorectal Cancer PathologyFoxp3 BiologyImmunosuppressive MicroenvironmentMicrosatellite Instability AnalysisMicrosatellite Instability BiomarkersPeripheral Regulatory T CellsTumor-associated Inflammation
AbstractImmune cells in the tumour microenvironment (TME) interact with each other and with tumour cells to promote tumour development. IL-6/STAT3 pathway induces and maintains mainly pro-tumour TME. Macrophages and lymphocytes are positive for IL-6, STAT3 and IL-17, while FoxP3 cells are mainly regulatory cells. IL-17+ and FoxP3+ immune cells have impact on gut inflammation and tumourigenesis. The aim of this study was to determine IL-6+, STAT3+, IL-17+ and FoxP3+ immune cells in colorectal cancer (CRC) TME and explore their association with clinicopathological parameters and mismatch repair (MMR) status. The investigated samples were collected from 104 CRC patients. Immunohistochemistry for the aforementioned markers and microsatellite instability (MSI) markers was performed. MSI testing was used. The investigated immune cells were significantly more in the invasive front (IF) as compared to tumour stroma (TS). IL-6+ and STAT3+ immune cells were more in the early tumour stages as compared to advanced stages. IL-17+ and IL-6+ immune cells were more in well and moderately differentiated cancers. IL-6+, STAT3+ and IL-17+ immune cells prevailed in the TME in microsatellite stable patients and only FoxP3+ cells were fewer there. Higher numbers of STAT3+ cells correlated with longer survival. These results support the suggestion that the transition of normal colonic mucosa to CRC is marked by a shift of Th programme, leading to accumulation of Th17 cells and Tregs that sustain tumour cell growth through the IL-6/STAT3 signalling pathway.
46
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Lin Wang, Tangsheng Yi, Marcin Kortylewski et al. · The Journal of Experimental Medicine · 2009 · 832 citations · Full text
Medicine, Immunology, Oncology +17